"Some studies have shown there have been concerns with mislabeling, contamination, inconsistent dosing, meaning consumers may not even know what they're taking," Widmer said
Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C: Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses
GLP-1 agonists can affect mood: A case of worsened depression on Ozempic (semaglutide)
Some preclinical studies have explored DSIP in pain pathway models, investigating its interaction with opioid receptor systems and examining behavioral pain measures in animal subjects under controlled research conditions